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TSLP Induces Mast Cell Development and Aggravates
Allergic Reactions through the Activation of MDM2
and STAT6
Na-Ra Han1, Hyun-A Oh1, Sun-Young Nam1, Phil-Dong Moon1, Do-Won Kim2, Hyung-Min Kim1 and
Hyun-Ja Jeong3
Thymic stromal lymphopoietin (TSLP) is known to promote T helper type 2 cell–associated inflammation. Mast
cells are major effector cells in allergic inflammatory responses. We noted that the population and maturation of
mast cells were reduced in TSLP-deficient mice (TSLP / ). Thus, we hypothesized that TSLP might affect mast
cell development. We found that TSLP induced the proliferation and differentiation of mast cells from bone
marrow progenitors. TSLP-induced mast cell proliferation was abolished by depletion of mouse double minute 2
(MDM2) and signal transducers and activators of transcription 6 (STAT6), as an upstream activator of MDM2.
TSLP / , in particular, had a considerable deficit in the expression of MDM2 and STAT6. Also, the TSLP
deficiency attenuated mast cell–mediated allergic reactions through the downregulation of STAT6 and MDM2.
In an antibody microarray chip analysis, MDM2 expression was increased in atopic dermatitis patients. These
observations indicate that TSLP is a factor for mast cell development, and that it aggravates mast cell–mediated
immune responses.
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INTRODUCTION
Mast cells are among the major effector cells in allergic
inflammatory reactions (Nilsson et al., 1994). The number of
mast cells is increased by proliferation, migration, and survival
in atopic dermatitis (AD) (Kneilling and Ro¨cken, 2009) and
allergic rhinitis (Enerba¨ck et al., 1986). Mast cell progenitors
leave the bone marrow and complete their maturation in a
variety of tissues (Nakanishi, 2010). Stem cell factor (SCF)/c-
Kit and IL-3 signaling are essential for mast cell development
(Hu et al., 2007). Reports from recent studies indicate that
various factors mediate this mast cell development (Liu et al.,
2010). IL-6 promoted human mast cell development as a
cofactor of SCF (Saito et al., 1996). IL-9 was one of the most
important cytokines for mast cell growth and differentiation
(Jamur and Oliver, 2011).
Thymic stromal lymphopoietin (TSLP) is characterized to
promote the activation of B cells and dendritic cells (Ziegler
and Artis, 2010). TSLP signaling is initiated by means of a
heterodimer composed of the IL-7 receptor a chain and TSLP
receptor (TSLPR) (Liu, 2007). In contrast to the restricted
expression of TSLP, TSLPR is expressed in many immune
cells (e.g., dendritic cells, T cells, B cells, mast cells, and
monocytes), as well as in various tissues (He and Geha, 2010).
The oncoprotein mouse double minute 2 (MDM2) was
identified as a negative regulator of p53 (Brooks and Gu,
2011). The activation of MDM2 attenuated the activity of the
tumor suppressor p53 (Gopal et al., 2009). Thus, many studies
have implicated MDM2 in the development of cancer in
various cells and tissues (Inuzuka et al., 2010). Because of the
limited number of studies conducted so far, the pathological
functions of MDM2, related to inflammatory disease, remain
unclear. Recently, however, there have been reports that
MDM2 was highly expressed in chronic pancreatitis, lupus,
and rheumatoid arthritis (Taranto et al., 2005; Allam et al.,
2011). Even so, a mechanism involving MDM2 as an
emerging factor for mast cell development and AD remains
poorly defined.
Cytokines transmit their signals via activation of the signal
transducers and activators of transcription (STATs). STAT
activation induces the development, proliferation, differentia-
tion, migration, and death of apoptotic cells, depending on the
type of stimuli and cells (Leonard and O’Shea, 1998). TSLP
has been shown to activate STAT1, STAT3, STAT4, STAT5,
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and signal transducers and activators of transcription 6
(STAT6) in human dendritic cells (Arima et al., 2010).
STAT6 was required for the differentiation and expansion of
T cells (Zhu et al., 2001). However, the role of TSLP in STAT6
activation, in relation to mast cell development, has not yet
been elucidated.
TSLP has a crucial role in various inflammatory diseases
(Liu, 2007). TSLP is also an important mediator of cancer
progression (Olkhanud et al., 2011; Pedroza-Gonzalez et al.,
2011). MDM2 overexpression had an important role in mast
cell tumorigenesis (Wu et al., 2006) and actively contributed
to inflammatory responses (Mulay et al., 2013). Because TSLP
and MDM2 contribute to the pathogenesis of both
inflammation and cancer, we hypothesized that MDM2
could mediate TSLP-dependent allergic reactions. Herein,
we have evaluated whether STAT6 and MDM2 are critical
for TSLP-dependent mast cell development. Furthermore, we
have clarified the roles of STAT6 and MDM2 in mast cell–
mediated allergic reactions.
RESULTS
The population and maturation of mast cells are reduced in
TSLP-deficient mice
We noted that the numbers of mast cells in organs of wild-type
mice (WT) were significantly higher than those of TSLP-
deficient mice (TSLP / , Figure 1a; Supplementary
Figure S1a online). The c-Kit in WT was highly expressed
compared with that in TSLP / (Figure 1b; Supplementary
Figure S1b and c online). However, TSLP did not affect mRNA
expression of mast cell–specific markers (i.e., c-Kit, FceRIa,
and FceRIg) in bone marrow–derived mast cells (BMMCs)
(Supplementary Figure S1d online). From electron microscopy
scans, it was determined that only a few short microvilli
appeared on the surfaces of mast cells from TSLP / , and
that the size of the mast cells was also smaller than those of
WT (Figure 1c). In addition, mast cells from TSLP /
showed reductions in the number, size, and density of
granules (Figure 1d). However, there was little difference in
the levels of serum inflammatory cytokines between WT and
TSLP / (Supplementary Figure S1e online).
TSLP induces mast cell development
Given the considerable defects in the number of mast cells in
TSLP / , we sought to determine how TSLP may affect mast
cell proliferation. As shown in Figure 2a–d, TSLP significantly
promoted the proliferation of BMMCs, BMMC-derived cell
line IC-2 cells, and human mast cell line (HMC-1) cells. Next,
we sought to determine whether TSLP would regulate mast
cell differentiation from bone marrow progenitors. During the
culture of bone marrow cells with TSLP for 4 weeks, TSLP
induced BMMC differentiation similar to IL-3, but anti-TSLP-
neutralizing Abs efficiently blocked mast cell differentiation
(Figure 2e and f). Mast cell (FceRIþc-Kitþ ) differentiation by
TSLP was increased until 3 weeks, but declined there-
after (Figure 2e). In contrast, the number of TSLP-induced
FceRIþc-Kit cells was significantly increased in 4 weeks
(Supplementary Figure S2a online). TSLP had no effect on
apoptosis and the cell cycle (Supplementary Figure S2b
and c online). Furthermore, TSLP significantly promoted
TSLP-elicited mast cell proliferation similar to IL-3, but
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Figure 1. Population and maturation of mast cells are reduced in thymic stromal lymphopoietin (TSLP) / . (a) Several organs were stained with alcian
blue and safranine O. Mast cells were counted in five tissue sections randomly selected per mouse (mm2). *Po0.05; significantly different from mast cells of
wild-type mice (WT) (C57BL/6). (b) c-Kitþ (phycoerythrin) cells of dorsal skin were examined with a confocal laser-scanning microscope. Bar¼ 10mm. (c)
Scanning electron microscopy (SEM) shows morphological differences between cell surface microvilli (arrow) and size in dorsal skin from WT and TSLP /
(original magnification  15,000). Bar¼3mm. (d) Transmission electron microscopy (TEM) shows numerous secretory granules that have released their contents
(arrowheads). Tissues from both WT and TSLP / have numerous intact granules (arrow). G, granules; N, nucleus (original magnification  10,000). Bar¼2mm.
N-R Han et al.
TSLP in Mast Cell–Mediated Allergic Reactions
2522 Journal of Investigative Dermatology (2014), Volume 134
anti-TSLP-neutralizing Abs significantly decreased the prolif-
eration (Figure 2g). No differences were observed between
TSLP- and IL-3-elicited mast cells in terms of morphology and
mast cell–specific protease expressions (Figure 2h; Supple-
mentary Figure S3a online). We confirmed that IL-7 receptor
a chain mRNA and TSLPR mRNA were expressed in TSLP- or
IL-3-elicited mast cells (Supplementary Figure S3b online).
Imprinting control region and BALB/c mice had significantly
more c-KitþFceRIþ mast cells compared wtih C57BL/6 mice in
the strain difference of mast cell development (Supplementary
Figure S3c online). IgE crosslinking significantly increased the
release of histamine and cytokines from the TSLP-elicited mast
cells (Supplementary Figure S3d online). To confirm the effect
of TSLP in mast cell development, BMMCs were induced by the
in vitro culture of bone marrow progenitors from WT and
TSLP / with TSLP or IL-3. However, the number of c-Kitþ
FceRIþ mast cells was indistinguishable between WT and
TSLP / (Supplementary Figure S4 online).
MDM2 is required for mast cell proliferation
We evaluated whether TSLP would induce mast cell prolifera-
tion through the upregulation of MDM2 expression. Interest-
ingly, TSLP increased MDM2 expression, whereas it decreased
p53 expression in each cell (Figure 3a). TSLP induced Bcl2
expression, but decreased poly ADP-ribose polymerase clea-
vage and caspase-3 activity (Figure 3b and c). IL-13 promotes
mast cell proliferation, but transforming growth factor-b and
granulocyte-macrophage colony–stimulating factor (GM-CSF)
inhibit mast cell proliferation (Liu et al., 2010). TSLP
significantly increased the production of IL-13 but decreased
the production of GM-CSF and transforming growth factor-b in
HMC-1 cells (Figure 3d and e). Furthermore, in TSLP / ,
mRNA and protein expression of MDM2 was significantly low
in each organ (Figure 3f and g).
To confirm that MDM2 is critical for the TSLP-dependent
proliferation and differentiation of mast cells, we knocked
down MDM2 with small interfering RNA (siRNA)
(Supplementary Figure S5a–c online). MDM2-siRNA signifi-
cantly reduced the mast cell proliferation and survival induced
by TSLP (Figure 3h and I; Supplementary Figure S5d online). In
addition, MDM2 deficiency lowered the production of TSLP-
induced IL-13, whereas GM-CSF production was decreased
further (Figure 3j and k). However, MDM2 did not affect
BMMC differentiation (Supplementary Figure S6 online).
STAT6 is required for TSLP-elicited mast cell development
STAT6 has an important role in the proliferation and differ-
entiation of a variety of cells (Suzuki et al., 2000). We
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Figure 2. Thymic stromal lymphopoietin (TSLP) induces mast cell development. (a) Bone marrow cells were cultured with IL-3 for 2 weeks and treated
with TSLP for 3 days. (b) IC-2 cells were cultured with TSLP or IL-3 for 3 days. Bar¼ 30mm. (c) HMC-1 cells were stimulated with TSLP or neutralizing antibody
(Ab) for 2 days. (d) Viability was measured with an 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay. (e) Bone marrow cells were gated
on live mast cells by flow cytometry. (f) Bone marrow cells were cultured with TSLP or neutralizing Ab for 3 weeks. (g) Bone marrow cells were cultured with
TSLP for 2 weeks and treated with IL-3, TSLP, or neutralizing Ab for 3 days. (h) Sorted mast cells were stained with alcian blue and safranine O (A&S) or
toluidine blue. Bar¼ 40mm.
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analyzed the phosphorylation of STAT6 (pSTAT6) by TSLP in
various mast cells (BMMCs, IC-2 cells, and HMC-1 cells).
Similar to IL-3, TSLP induced pSTAT6 in BMMCs. TSLP
induced pSTAT6 in each cell line (Figure 4a). We confirm
that TSLP also induced pSTAT5 in HMC-1 cells (Supple-
mentary Figure S7 online). In agreement with the differentia-
tion and proliferation data, we noted a reduction in mast cells
expressing pSTAT6 in each tissue of TSLP / compared
with WT (Figure 4b). The proliferation of STAT6-deficient
bone marrow cells by TSLP was lower than that in WT
(Figure 4c). Similarly, the STAT6-deficient bone marrow cells
died rapidly in the presence of TSLP or IL-3 (Figure 4d and e).
STAT6 induces T helper type 2 (Th2) cell development
through the transcription of GATA3 associated with MDM2
(Yamashita et al., 2005). Thus, we performed an immuno-
precipitation experiment to determine whether the pSTAT6
induced by TSLP would directly interact with MDM2. When
MDM2 was immunoprecipitated from nuclear extracts of
TSLP-stimulated HMC-1 cells, STAT6 was identified in
nuclear extracts (Figure 4f). When MDM2-immunoprecipitated
proteins were immunoblotted with anti-p53 antibody, the
result was reduced p53 detection from nuclear extracts. When
STAT6 was immunoprecipitated from nuclear extracts, MDM2
was identified (Figure 4f). The STAT6–MDM2 complex
induced by TSLP was not detected in each cytoplasmic extract.
A STAT6 inhibitor, leflunomide, decreased MDM2 expression
by TSLP (Figure 4g). The mRNA and protein expression of
MDM2 was less in STAT6-deficient mice (STAT6 / ,
Figure 4h and i). Furthermore, the MDM2 mRNA expression
was less in STAT6-deficient bone marrow cells (Figure 4j).
TSLP and STAT6 promote mast cell–mediated allergic reactions
TSLP and STAT6 mediate Th2 type immunity. We tested mast
cell–mediated allergic reactions in TSLP / . In TSLP / ,
systemic anaphylactic reaction and passive cutaneous anaphy-
laxis (PCA) were significantly inhibited compared with those in
WT (Figure 5a and b). The levels of IL-6 were downregulated in
the PCA sites of TSLP / (Figure 5c and d). In STAT6 / ,
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Figure 3. MDM2 is required for mast cell proliferation. Cells were stimulated with thymic stromal lymphopoietin (TSLP) for (a) 8 hours or (b) 48 hours and
western blot analysis was performed. (c) Caspase-3 activity was measured 48 hours after stimulation with TSLP in HMC-1 cells. (d, e) Production was
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systemic anaphylactic and PCA reactions were significantly
inhibited compared with those in WT (Figure 5e–g). The
numbers of mast cells at PCA sites of STAT6 / were
smaller than those of WT (Figure 5h). Furthermore, the levels
of serum IL-6, TNF-a, and IgE of STAT6 / were signifi-
cantly lower than those of WT (Figure 5i).
MDM2 by TSLP increases AD reactions
We confirmed that the mRNA expression and protein levels of
TSLP were significantly increased in DNFB-induced AD-like
dorsal skin lesions in NC/Nga mice (Supplementary Figure S8a
and b online). The clinical symptoms, epidermis thickness,
scratching behavior, and serum histamine levels were less in
DNFB-sensitized TSLP / compared with DNFB-sensitized
WT (Supplementary Figure S8c–f online). Also, the expression
of cytokines and chemokines was less in lesions of TSLP /
compared with those of WT (Supplementary Figure S8g–i
online). TSLP significantly induced the production of inflam-
matory cytokines in HMC-1 cells (Supplementary Figure S8j
online).
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To investigate that MDM2 regulates AD, we analyzed the
expressions of proteins related to cell signaling in the skin of
AD patients using the antibody microarray chip. MDM2
was markedly increased, whereas p53 was decreased in AD
patients (Figure 6a and b). Next, we assessed the MDM2 levels
in lesions. The MDM2 mRNA expression was increased in ear
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Figure 5. Thymic stromal lymphopoietin (TSLP) and signal transducers and activators of transcription 6 (STAT6) promote mast cell–mediated allergic reactions.
(a) Intraperitoneal injections were given with compound 48/80 to wild-type mice (WT) or TSLP / (n¼ 5). (b) The amount of dye based on passive
cutaneous anaphylaxis (PCA) reaction was calculated with a spectrophotometer (n¼5). (c) mRNA expression in skin tissues under PCA reaction was analyzed
using reverse transcription-PCR analysis. (d) Serum cytokines were measured from mice under PCA reaction by ELISA. (e) Intraperitoneal injections were given
with compound 48/80 to WT or STAT6 / (n¼ 6). (f) Serum histamine was assayed from mice under systemic anaphylactic reaction. (g) The amount
of dye based on PCA reaction was calculated with a spectrophotometer (n¼6). (h) Skin tissues under PCA reaction were stained by alcian blue–nuclear fast red.
(i) Serum cytokines were measured from mice under PCA reaction by ELISA.
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lesions (Figure 6c). The mRNA and protein expressions of
MDM2 were also increased in DNFB-induced lesions com-
pared with controls (Figure 6d). Furthermore, we sought to
verify whether MDM2 would be induced by TSLP amplified
in AD. The expression of MDM2 was less in lesions of
TSLP / compared with those of WT (Figure 6e). Also,
the number of MDM2þc-Kitþ cells was less in lesions
of TSLP / compared with those of WT (Figure 6f;
Supplementary Figure S9 online).
Finally, the mice were treated with MDM2-siRNA injections
into DNFB-sensitized lesions to confirm that MDM2 is a
critical factor for AD. The mRNA expression of cytokines and
chemokines was less in MDM2-deficient lesions compared
with those of control lesions (Figure 6g). Interestingly, mRNA
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and protein levels of TSLP were lower in MDM2-deficient
lesions than in control lesions (Figure 6g and h). Apoptosis in
MDM2-deficient lesions occurred at a higher level than in
control lesions (Figure 6i–k). MDM2 deficiency decreased
tryptase activity (Figure 6l), which reflected impaired mast cell
proliferation.
DISCUSSION
Mast cells are recognized as critical effector cells in allergic
inflammatory diseases (Nilsson et al., 1994) and are present in
the bone marrow as mast cell precursors. The microenviron-
ment surrounding a mast cell determines the mast cell
phenotype (Jamur and Oliver, 2011). Bone marrow cultured
in the presence of TSLP for 5 days alone promoted basophil
hematopoiesis, but not mast cell development (Siracusa et al.,
2011). However, we found that, similar to IL-3, mouse
TSLP induced the development of mast cells from bone
marrow progenitors, when they were cultured for a long
time in media containing TSLP. The number of mast cells
and c-Kit mRNA expression were decreased in TSLP / .
However, TSLP did not affect mRNA expression of mast
cell–specific markers in BMMCs. Therefore, we speculated
that the various growth factors and cytokines released from
bone marrow–derived cells cultured with TSLP might affect
mast cell differentiation.
TSLP increased the mast cell development until 3 weeks of
culture but decreased it thereafter. Interestingly, the number of
FceRIþc-Kit cells was increased without change in the total
cell number in 4 weeks. Like the trait of TSLP in mast cells,
macrophage colony–stimulating factor, which is the main
regulator of the proliferation, survival, and differentiation of
mononuclear phagocytes, increased the number of bone
marrow–derived macrophages until day 7 of culture and
decreased it at day 10 (Otero et al., 2009). The
costimulation by IL-3 and SCF elicited the differentiation of
progenitor cells into immature BMMCs, and then stimulated
their proliferation, whereas costimulation by IL-3 and IL-4
inhibited the final stages of differentiation and maturation of
mast cells (Eklund et al., 1993). We speculated that TSLP
might induce secretion of various growth factors and cytokines
that impact BMMC development and that these might inhibit
mast cell differentiation and maturation after 3 weeks. Further
work is necessary to clarify how TSLP contributes to mast cell
biology under the conditions in which the development of
mast cell progenitors from bone marrow was limited.
Cell development is modulated through the interaction of a
number of factors. The MDM2–p53 pathway determines the
proliferation or death of tumor cells (Lee and Gu, 2010). The
p53 mediates apoptotic proteins (e.g., caspase-3 and poly
ADP-ribose polymerase) and antiapoptotic proteins (e.g., Bcl2)
(Munagala et al., 2011). Moreover, caspase-3, poly ADP-
ribose polymerase, and Bcl2 are involved in AD or asthma
(Lin et al., 2007; Tezcan et al., 2009). We found that TSLP
increased antiapoptotic factors (MDM2, IL-13, and Bcl2) and
decreased apoptotic factors (transforming growth factor-b,
GM-CSF, p53, and caspase-3). We also showed that the lack
of MDM2 in mast cells markedly increased mast cell apoptosis
through the inhibition of antiapoptotic factors and the
activation of apoptosis factors in DNFB-sensitized lesions.
Even so, TSLP had no effect on the apoptosis of bone marrow
cells during their development. The upregulation of MDM2 by
TSLP did not affect mast cell differentiation and only promoted
mast cell proliferation. These data indicate that TSLP promotes
the mast cell proliferation through the modulation of
apoptotic/antiapoptotic factors by MDM2. Opportunely, the
level of TSLP was less in MDM2-deficient lesions than in
control lesions. MDM2-deficient mice exhibited lower
tryptase activity compared with control mice. These results
suggest that mast cell proliferation by MDM2 might have an
important role in TSLP-related inflammatory reaction.
TSLP induces Th2 responses and leads to the development
of AD (Jariwala et al., 2011). TSLPR deficiency showed greatly
reduced allergic skin inflammation compared with WT (He
et al., 2008). STAT6-siRNA inhibited the infiltration of
inflammatory cells into mucosal tissues of those with allergic
rhinitis (Hosoya et al., 2011). STAT6 / have impaired Th2
differentiation and reduced airway response to the allergen
(Chapoval et al., 2011). STAT6 activation in fibroblasts
supports mast cell maturation (Nabeshima et al., 2005).
STAT6 contributed to the proliferation and growth of mast
cells (Suzuki et al., 2000). We showed that STAT6 / failed
to generate mast cell development in response to TSLP or IL-3,
and that it induced the apoptosis of bone marrow progenitors.
Moreover, the numbers of mast cells and cytoplasmic
granules, as well as PCA reactions, were reduced in TSLP /
 and STAT6 / . Taken together, these results imply that
TSLP and STAT6 are critical factors for maintaining mast cell
proliferation and differentiation, and in aggravating mast cell–
mediated allergic reactions. Therefore, the reduction of mast
cell–mediated allergic reactions in TSLP / and STAT6 /
 might be associated with a decrease in mast cell
development.
MDM2 is overexpressed in various tumors and thereby
attenuates the function of the tumor suppressor p53. STAT6
promotes the gene expression related to prometastasis and
antiapoptosis, which leads to tumor growth (Li et al., 2012).
Interestingly, pSTAT6 in HT-29 cells increased mRNA
expression of MDM2; on the other hand, STAT6-deficient
Caco-2 cells decreased mRNA expression of MDM2 (Li et al.,
2008). MDM2 is also associated with the ubiquitination of
GATA3, which is required to differentiate Th2 cells (Yamashita
et al., 2005). Notably, we found that the interaction between
STAT6 and MDM2 induced by TSLP occurred in nuclei and
that STAT6 inhibitor inhibited MDM2 expression induced by
TSLP in HMC-1 cells. The mRNA expression of MDM2 was
less in TSLP / and STAT6 / . Therefore, STAT6 might
induce MDM2 expression, and the interaction between STAT6
and MDM2 in a nucleus might promote TSLP-elicited mast
cell proliferation.
The importance of mast cells in allergic diseases, host
defense, and inflammation has been recognized. This paper
describes the biological features involving TSLP in mast cell
development. We also show that MDM2 and STAT6 partially
upregulate TSLP signaling, with obvious effects on mast cell
biology (Supplementary Figure S10 online). In conclusion, the
data further emphasize the prominent role of TSLP in mast
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cell–mediated diseases. More knowledge about mast cells
could lead to cures for diseases in which mast cells have
significant roles.
MATERIALS AND METHODS
Mice
We maintained 6-week-old female BALB/c, imprinting control region,
and C57BL/6 (Charles River Laboratories, Wilmington, MA) mice
under specific pathogen-free conditions. TSLP / and STAT6 /
were purchased from the KOMP Repository (Grant #
5U01U01HG004085, California, CA) and Jackson Laboratory (Bar
Harbor, ME), respectively. The homozygous TSLP / and
STAT6 / were identified by PCR. Mouse care and experimental
procedures were performed under approval from the Animal Care
Committee of Kyung Hee University (KHUASP(SE)-12-019).
Cell culture
BMMCs were generated from femoral bone marrow cells of female
mice. Cells were incubated in RPMI 1640 (Sigma-Aldrich, St Louis,
MO) supplemented with 10% heat-inactivated fetal bovine serum,
100 U ml 1 penicillin, 100mg ml 1 streptomycin, 100mM 2-mercap-
toethanol, 10 mM sodium pyruvate, 10mM MEM nonessential amino
acid solution (Invitrogen, Carlsbad, CA), IL-3, TSLP, SCF, and TSLP-
neutralizing Abs (R & D system, Minneapolis, MN). IC-2 cells were
grown in a-Minimum Essential Medium from Gibco BRL (Grand
Island, NY) with IL-3. HMC-1 cells were grown in Isocove’s Modified
Dulbecco’s Medium from Gibco BRL. The cells were cultured at
37 1C in a humidified atmosphere in the presence of 5% CO2.
PCA reaction
An IgE-dependent cutaneous reaction was generated by sensitizing
skin with an intradermal injection of anti-dinitrophenyl (DNP) IgE
(Sigma-Aldrich), followed 48 hours later with an injection of DNP–
human serum albumin into the mouse tail vein. The DNP–human
serum albumin was diluted in phosphate-buffered saline. The mice
were injected intradermally with 100 ng of anti-DNP IgE into each of
three dorsal skin sites that had been shaved 48 hours earlier and were
outlined with a water-insoluble red marker. Forty-eight hours later,
each mouse received an injection of 200ml of the 1:1 mixture of
1 mg ml 1 DNP–human serum albumin in phosphate-buffered
saline and 4% Evans blue via tail vein. The mice were euthanized
40 minutes after the intravenous challenge and the dorsal skin
of each mouse was removed for measurement of the pigment area.
The amount of dye was determined colorimetrically after extraction
with 0.5 ml of 1.0 M KOH and 4.5 ml of a mixture of acetone
and phosphoric acid (with the ratio of 5:13). The absorbent
intensity of the extraction was measured at 620 nm in a spectro-
fluorometer and the amount of dye was calculated with an Evans
blue measuring line. Blood was drawn from the hearts of mice
into syringes. Serum was prepared by centrifugation at 3,000g at 4 1C
for 10 minutes.
Systemic anaphylactic reaction
Mice were given an intraperitoneal injection of the mast cell
degranulator, compound 48/80 (8 mg kg 1). Mortality was monitored
for 30 minutes after the induction of the anaphylactic reaction.
Mortality (%) is presented as the ‘‘number of dead mice 100/total
number of experimental mice’’. Saline was used for treatments of the
control animals in all experiments. Saline did not yield any obser-
vable effects in any of the experiments.
Human research
This study was approved by the Ethics Committee of Kyungpook
National University Hospital in Daegu, Republic of Korea (KNUH-09-
1018). Written informed patient consent was obtained and the study
was conducted according to Declaration of Helsinki Principles.
Human skin samples were collected from normal controls and AD
patients between August 2008 and May 2010. After the injection of a
local anesthetic, biopsy specimens were taken from the normal
controls (n¼ 4; three males, one female; age: 20.0±4.2) and the
untreated lesional skin of AD patients (n¼ 6; five males, one female;
age: 16.7±8.1).
Sensitization with DNFB
For active sensitization, 100ml of 0.15% DNFB dissolved in acetone
or acetone (vehicle controls) was topically applied to the shaved
abdominal skin of NC/Nga, C57BL/6 (WT), or TSLP / . A week
later, the mice were sensitized with DNFB by applying it to the
shaved dorsal skin with 50ml of 0.15% DNFB or acetone twice a
week for 3 weeks. The sera from heart and skin samples were
obtained 4 hours after the last DNFB challenge.
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